Clinical Considerations for Glucocorticoid Use in IgG4-Related Disease

Immunoglobulin G4–related disease (IgG4-related disease) is a chronic, immune-mediated fibroinflammatory disorder that can involve nearly any organ system and often requires therapy to control disease activity while limiting treatment burden. In the phase 3 INDIGO trial published in The New England Journal of Medicine, investigators evaluated weekly subcutaneous obexelimab in adults with active IgG4-related disease after standardized glucocorticoid induction and tapering, underscoring the importance of understanding how glucocorticoids fit into current treatment strategies.

©2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Consultant360 or HMP Global, their employees, and affiliates.